专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2011029996A1 USE OF VAP-1 INHIBITORS FOR TREATING FIBROTIC CONDITIONS 审中-公开
标题翻译：使用VAP-1抑制剂治疗纤维状态
公开(公告)号：WO2011029996A1
公开(公告)日：2011-03-17
申请号：PCT/FI2010/050689
申请日：2010-09-07
申请人： BIOTIE THERAPIES CORP. , THE UNIVERSITY OF BIRMINGHAM , WESTON, Christopher , CLARIDGE, Lee, Charles , ADAMS, David , SMITH, David , WESTERLUND, Nina , PIHLAVISTO, Marjo , ÖSTERMAN, Thua
发明人： WESTON, Christopher , CLARIDGE, Lee, Charles , ADAMS, David , SMITH, David , WESTERLUND, Nina , PIHLAVISTO, Marjo , ÖSTERMAN, Thua
IPC分类号： A61K39/395 , A61K31/00 , A61P17/02 , A61P43/00 , C07K16/40 , G01N33/577
CPC分类号： A61K39/3955 , A61K31/00 , A61K31/137 , A61K31/185 , A61K2039/505 , C07K16/40 , C07K2317/76 , G01N33/573 , G01N33/6893 , G01N2333/90638 , G01N2800/085
摘要： The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.
摘要翻译：本发明涉及VAP-1抑制剂及其作为药物治疗纤维化病症的用途。此外，本发明涉及基于体液中可溶性VAP-1或SSAO活性水平升高以及用于所述诊断方法的试剂盒诊断纤维化病症的方法。

2. 发明申请

WO2010063292A1 NALMEFENE HYDROCHLORIDE DIHYDRATE 审中-公开
标题翻译： NALMEFENE氢氯化物二水合物
公开(公告)号：WO2010063292A1
公开(公告)日：2010-06-10
申请号：PCT/DK2009/050320
申请日：2009-12-04
申请人： H. LUNDBECK A/S , BIOTIE THERAPIES CORP. , LOPEZ DE DIEGO, Heidi , DE FAVERI, Carla , HUBER, Florian Anton Martin
发明人： LOPEZ DE DIEGO, Heidi , DE FAVERI, Carla , HUBER, Florian Anton Martin
IPC分类号： C07D489/08 , A61K31/485 , A61P25/30
CPC分类号： C07D489/08
摘要： The present invention relates to the Nalmefene hydrochloride dihydrate, methods of manufacturing Nalmefene hydrochloride dihydrate, a pharmaceutical composition comprising Nalmefene hydrochloride dihydrate and a method of treatment comprising administering Nalmefene hydrochloride dehydrate.
摘要翻译：本发明涉及盐酸纳美芬，二水合盐酸纳美芬的制备方法，盐酸纳美芬酸二水合物的药物组合物及其制备方法，该方法包括给予盐酸纳美芬无水物。

3. 发明申请

WO2004041291A9 HIGH AFFINITY RECEPTORS FOR HELICOBACTER PYLORI AND USE THEREOF 审中-公开
标题翻译： HELICOBACTER PYLORI的高亲和力受体及其用途
公开(公告)号：WO2004041291A9
公开(公告)日：2004-07-22
申请号：PCT/FI0300840
申请日：2003-11-06
申请人： BIOTIE THERAPIES CORP , TENEBERG SUSANN , MILLER-PODRAZA HALINA , NATUNEN JARI , KARLSSON KARL-ANDERS
发明人： TENEBERG SUSANN , MILLER-PODRAZA HALINA , NATUNEN JARI , KARLSSON KARL-ANDERS
IPC分类号： A61K8/68 , A61K8/73 , A61K31/7012 , A61K31/702 , A61K31/7032 , A61K31/715 , A61P1/04 , A61Q5/02 , A61Q11/00 , A61Q17/00 , A61Q19/00 , A61Q19/10 , C08B37/00
CPC分类号： A61Q17/005 , A61K8/68 , A61K8/73 , A61K31/7012 , A61K31/702 , A61K31/7032 , A61K31/715 , A61K39/105 , A61Q5/02 , A61Q11/00 , A61Q19/00 , A61Q19/10 , C08B37/006
摘要： The present invention describes an oligosaccharide substance or receptor binding to Helicobacter pylori, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori.
摘要翻译：本发明描述了结合幽门螺杆菌的寡糖物质或受体，以及其在例如药物和营养组合物中用于治疗幽门螺杆菌存在的病症的用途。本发明还涉及该受体用于诊断幽门螺杆菌的用途。

4. 发明申请

WO2008125738A2 A METHOD FOR SELECTING RESPONDERS TO BLOCKADE OF INTEGRIN RECEPTORS 审中-公开
标题翻译：一种选择响应者阻断整合受体的方法
公开(公告)号：WO2008125738A2
公开(公告)日：2008-10-23
申请号：PCT/FI2008050195
申请日：2008-04-16
申请人： BIOTIE THERAPIES CORP , MARJAMAEKI ANNE , NISSINEN LIISA
发明人： MARJAMAEKI ANNE , NISSINEN LIISA
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158
摘要： The present invention relates to a method for identifying responders to a blockade of integrin receptors, as well as to a method for determining responsiveness to a treatment involving with said blockade in a patient in need of such treatment. Furthermore, the present invention relates to a kit for use in said methods.
摘要翻译：本发明涉及用于鉴定对整联蛋白受体阻断的响应者的方法，以及涉及用于确定对需要这种治疗的患者的涉及所述阻断的治疗的响应性的方法。此外，本发明涉及用于所述方法的试剂盒。

5. 发明申请

WO03015783A8 METHOD OF TREATING ALCOHOLISM OR ALCOHOL ABUSE 审中-公开
标题翻译：治疗酒精或酒精的方法
公开(公告)号：WO03015783A8
公开(公告)日：2005-04-07
申请号：PCT/FI0200670
申请日：2002-08-13
申请人： BIOTIE THERAPIES CORP , KURKELA KAUKO , PUHAKKA OLLI , SONCK TUULI , KARHUVAARA SAKARI
发明人： KURKELA KAUKO , PUHAKKA OLLI , SONCK TUULI , KARHUVAARA SAKARI
IPC分类号： C07D489/08 , A61K9/20 , A61K9/48 , A61K31/485 , A61K45/00 , A61P25/32
CPC分类号： A61K31/485
摘要： The present invention relates to a method of treating alcoholism or alcohol abuse by administering to a subject a pharmaceutically effective amount of an opioid antagonist before imminent drinking, particularly, by administering said opioid antagonist transmucosally. Preferably, the opioid antagonist used in the method is nalmefene or a pharmaceutically acceptable salt thereof. The invention also relates to a method of treating alcoholism or alcohol abuse by administering to a subject before imminent drinking a transmucosal preparation having rapid onset of action. Advantageously, a FAH+ subject is treated. Further, the invention relates to a method of treating alcoholism or alcohol abuse of a FAH+ subject, comprising extinguishing an alcohol-drinking response by administering to the FAH+ subject a pharmaceutically effective amount of nalmefene or a pharmaceutically acceptable salt thereof.
摘要翻译：本发明涉及一种通过向受试者施用药物有效量的阿片样物质拮抗剂在即将饮酒之前，特别是通过经粘膜内施用所述阿片样物质拮抗剂来治疗酒精中毒或酒精滥用的方法。优选地，该方法中使用的阿片样物质拮抗剂是纳美芬或其药学上可接受的盐。本发明还涉及一种通过在即将饮用具有快速起效的经粘膜制剂之前给予受试者来治疗酒精中毒或酒精滥用的方法。有利地，治疗FAH +受试者。此外，本发明涉及一种治疗FAH +受试者的酒精中毒或酒精滥用的方法，包括通过向FAH +受试者施用药学有效量的纳美芬或其药学上可接受的盐来扑灭酒精饮酒反应。

6. 发明申请

WO02056893A8 NOVEL RECEPTORS FOR DOLLAR I(HELICOBACTER PYLORI) AND USE THEREOF 审中-公开
标题翻译： DOLLAR I（HELICOBACTER PYLORI）的新受体及其用途
公开(公告)号：WO02056893A8
公开(公告)日：2003-11-13
申请号：PCT/FI0200043
申请日：2002-01-18
申请人： BIOTIE THERAPIES CORP , MILLER-PODRAZA HALINA , TENEBERG SUSANN , AANGSTROEM JONAS , KARLSSON KARL-ANDERS , NATUNEN JARI
发明人： MILLER-PODRAZA HALINA , TENEBERG SUSANN , AANGSTROEM JONAS , KARLSSON KARL-ANDERS , NATUNEN JARI
IPC分类号： G01N33/53 , A61K31/43 , A61K31/702 , A61K31/715 , A61K39/00 , A61P1/04 , A61P1/16 , A61P1/18 , A61P9/00 , A61P31/04 , A61P35/00 , A61P37/06 , C07H3/06 , C12N1/00 , C12Q1/02 , G01N33/569 , C07H15/04
CPC分类号： A61K31/702
摘要： The present invention describes a substance or a receptor comprising Helicobacter pylori binding oligosaccharide sequence [Gal(A)q(NAc)r/Glc(A)q(NAc)r alpha 3/ beta 3]s[Gal beta 4GlcNAc beta 3]tGal beta 4Glc(NAc)u wherein q, r, s, t, and u are each independently 0 or 1, and the use thereof in, e.g., pharmaceutical and nutritional compositions for the treatment of conditions due to the presence of Helicobacter pylori. The invention is also directed to the use of the receptor for diagnostics of Helicobacter pylori.
摘要翻译：本发明描述了幽门螺杆菌结合寡糖序列[Gal（A）q（NAc）r / Glc（A）q（NAc）rα3 /β3] s [Galβ4GlcNAcβ3] tGal的物质或受体 β4G1c（NAc）u其中q，r，s，t和u各自独立地为0或1，以及其在例如药物和营养组合物中用于治疗幽门螺杆菌存在的病症的用途。本发明还涉及该受体用于诊断幽门螺杆菌的用途。

7. 发明申请

WO0246379A3 GLUCURONYL C5-EPIMERASE, DNA ENCODING THE SAME AND USES THEREOF 审中-公开
标题翻译： GLUCURONYL C5-EPIMERASE，编码它们的DNA及其用途
公开(公告)号：WO0246379A3
公开(公告)日：2003-11-06
申请号：PCT/FI0101068
申请日：2001-12-07
申请人： BIOTIE THERAPIES CORP
发明人： JALKANEN MARKKU , EL DARWISH KAMEL , LINDAHL ULF , LI JIN-PING
IPC分类号： C12N15/09 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N9/90 , C12N15/61
CPC分类号： C12N9/90 , C12Y501/03012
摘要： The invention is directed to a novel purified mouse C5-epimerase, fragments thereof, nucleic acids encoding the same and the recombinant production thereof. The invention is also directed to fragments of such epimerase, especially N-terminal fragments that are useful in fusion protein constructs to enhance the activity of recombinantly-produced heterologous epimerase enzymes.
摘要翻译：本发明涉及新型纯化的小鼠C5-差向异构酶，其片段，编码它们的核酸及其重组生产。本发明还涉及这种差向异构酶的片段，特别是可用于融合蛋白构建体以增强重组产生的异源差向异构酶的活性的N-末端片段。

8. 发明申请

WO2004031244A1 NOVEL CARBOHYDRATE COMPOSITIONS AND A PROCESS OF PREPARING SAME 审中-公开
标题翻译：新型碳酸氢盐组合物及其制备方法
公开(公告)号：WO2004031244A1
公开(公告)日：2004-04-15
申请号：PCT/FI2003/000734
申请日：2003-10-06
申请人： BIOTIE THERAPIES CORP. , HELIN, Jari , NATUNEN, Jari , LEHTILÄ, Reko , ROSLUND, Mattias , LEINO, Reko
发明人： HELIN, Jari , NATUNEN, Jari , LEHTILÄ, Reko , ROSLUND, Mattias , LEINO, Reko
IPC分类号： C08B37/00
CPC分类号： C07H3/04 , C07H1/00 , C07H3/06 , C07H5/06 , C08B37/00
摘要： The present invention is directed to novel methods to produce carbohydrate polymers and oligomers especially for pharmaceutical and food industries. The invention is directed to methods to remodel monosaccharides, and/or oligosaccharides and/or polysaccharides by a different monosaccharide, oligosaccharide or polysaccharide and optionally by further alcohol substances, under condensing conditions, preferably in acid catalysed reactions.
摘要翻译：本发明涉及制备碳水化合物聚合物和低聚物的新方法，特别是用于制药和食品工业。本发明涉及在冷凝条件下，优选在酸催化的反应中，通过不同的单糖，寡糖或多糖和任选的其它醇物质改造单糖和/或寡糖和/或多糖的方法。

9. 发明申请

WO0202541A3 INHIBITORS OF COPPER-CONTAINING AMINE OXIDASES 审中-公开
标题翻译：含铜胺氧化物的抑制剂
公开(公告)号：WO0202541A3
公开(公告)日：2002-04-18
申请号：PCT/FI0100637
申请日：2001-07-04
申请人： BIOTIE THERAPIES CORP , SMITH DAVID JOHN , JALKANEN MARKKU , FUELOEP FERENC , LAZAR LASZLO , SZAKONYI ZSOLT , BERNATH GABOR
发明人： SMITH DAVID JOHN , JALKANEN MARKKU , FUELOEP FERENC , LAZAR LASZLO , SZAKONYI ZSOLT , BERNATH GABOR
IPC分类号： C07D217/16 , A61K31/00 , A61K31/131 , A61K31/14 , A61K31/15 , A61K31/40 , A61K31/445 , A61K31/472 , A61K31/5395 , A61P1/04 , A61P1/16 , A61P3/00 , A61P3/10 , A61P9/00 , A61P9/10 , A61P11/06 , A61P17/00 , A61P19/02 , A61P25/00 , A61P29/00 , A61P37/00 , A61P43/00 , C07B61/00 , C07D273/04 , C07D498/04 , C07D498/10
CPC分类号： A61K31/131 , A61K31/14 , A61K31/15 , A61K31/40 , A61K31/445 , A61K31/472
摘要： The present invention is directed to 1,3,4-oxadiazine compounds that function as inhibitors of copper-containg amine oxidases commonly known as semicarbazide-sensitive amine oxidases (SSAO), including the human SSAO known as Vascular Adhesion Protein-1 (VAP-1). These SSAO inhibitors have therapeutic utility as drugs to treat conditions and diseases including, but not limited to, a number of inflammatory conditions and diseases (in particular chronic inflammatory conditions such as chronic arthritis, inflammatory bowel diseases, and chronic skin dermatoses), diseases related to carbohydrate metabolism and to abberations in adipocyte differentiation or function and smooth muscle cell function, and vascular diseases. The compounds have the general formula (I): or a tautomer, isomer, hydrazino alcohol degradation product, or a pharmaceutically acceptable solvate, hydrate, or salt thereof, wherein R , R , R , R , R ,R , R , and R are as defined her ein.
摘要翻译：本发明涉及用作通常称为氨基脲敏感性胺氧化酶（SSAO）的含铜胺氧化酶抑制剂的1,3,4-恶二嗪化合物，其包括称为血管粘附蛋白-1（VAP- 1）。这些SSAO抑制剂具有用于治疗病症和疾病的药物的治疗用途，包括但不限于许多炎性病症和疾病（特别是慢性炎症病症如慢性关节炎，炎性肠病和慢性皮肤皮肤病），相关疾病到碳水化合物代谢和脂肪细胞分化或功能和平滑肌细胞功能的消退，以及血管疾病。所述化合物具有通式（I）：或互变异构体，异构体，肼醇降解产物或其药学上可接受的溶剂合物，水合物或盐，其中R 1，R 2，R 3，R R 5，R 5，R 6，R 7和R 8如此定义。

10. 发明申请

WO2010146236A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES 审中-公开
标题翻译：尿素取代的磺酰胺衍生物
公开(公告)号：WO2010146236A1
公开(公告)日：2010-12-23
申请号：PCT/FI2010/050495
申请日：2010-06-14
申请人： BIOTIE THERAPIES CORP. , KORHONEN, Jani , MARJAMÄKI, Anne , NISSINEN, Liisa , PIHLAVISTO, Marjo
发明人： KORHONEN, Jani , MARJAMÄKI, Anne , NISSINEN, Liisa , PIHLAVISTO, Marjo
IPC分类号： C07C311/21 , C07D231/18 , C07D401/04 , C07D409/04 , C07D413/04 , C07D415/00 , C07D213/34 , C07D209/40 , C07D213/60 , C07D333/34 , C07D319/18 , C07D277/36 , C07D409/14 , A61K31/18 , A61P7/02 , A61P9/00 , A61P11/06 , A61P17/06 , A61P19/02 , A61P35/00 , A61P37/00
CPC分类号： C07D213/75 , C07C311/21 , C07C311/29 , C07C311/47 , C07D209/08 , C07D213/34 , C07D213/40 , C07D213/71 , C07D213/76 , C07D231/12 , C07D231/18 , C07D231/38 , C07D231/40 , C07D233/84 , C07D277/36 , C07D319/18 , C07D333/34 , C07D401/04 , C07D409/04 , C07D409/14 , C07D413/04 , C07D417/04
摘要： The present invention relates to sulphonamide derivatives, whith a urea moiety. The invention also relates to the use of the derivatives as inhibitors of collagen receptor integrins, especially α2β1 integrin inhibitors e.g. in connection with diseases and medical conditions that involve the action of cells and platelets expressing collagen receptors, their use as a medicament, e.g. for the treatment of thrombosis, inflammation, cancer and vascular diseases, pharmaceutical compositions containing them and a process for preparing them. The sulphonamide derivatives have the general formula (I) or (I').
摘要翻译：本发明涉及一种尿素部分的磺酰胺衍生物。本发明还涉及衍生物作为胶原受体整合素抑制剂的用途，特别是a2β1整联蛋白抑制剂。涉及涉及表达胶原受体的细胞和血小板的作用的疾病和医学病症，它们作为药物的用途，例如，用于治疗血栓形成，炎症，癌症和血管疾病，含有它们的药物组合物及其制备方法。磺酰胺衍生物具有通式（I）或（I'）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式